V
Virginia F. Borges
H-index:60
Citation Count:1.3万
Views:0
Biography
No content for now.
Education
No content for now.
Work Experience
No content for now.
Honors & Awards
No content for now.
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial
POSITIVE试验(女性内分泌敏感性乳腺癌中断治疗的妊娠结局与安全性)最新结果
Annals of Oncology
IF65.4
Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort
胚系BRCA1/2携带者两组匹配队列的研究结果与治疗模式
JNCI Cancer Spectrum
IF4.1
Psychosocial support utilization among breast cancer patients experiencing reproductive concerns: A cross-sectional cohort study
乳腺癌患者中存在生殖问题的患者的心理社会支持利用情况:一项横断面队列研究
ACR Appropriateness Criteria® Breast Imaging During Pregnancy
ACR Appropriateness Criteria®孕期乳腺影像检查
Corrigendum to “Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]
勘误:“Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial” [The Breast 83 (2025) 104547]
The Breast
IF0
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial
POSITIVE试验中,预测乳腺癌患者为尝试生育而中断辅助内分泌治疗时生育力的激素因素
breast
IF0
Sequential Therapy With HER2 Tyrosine Kinase Inhibitors in Patients With HER2-Positive Metastatic Breast Cancer
HER2酪氨酸激酶抑制剂序贯疗法在HER2阳性转移性乳腺癌患者中的应用
Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy
二线化疗进展后的转移性三阴性乳腺癌患者中Imprime与Pembrolizumab免疫疗法的二期临床试验

